New radiation drug targets tough prostate cancer in early trial
NCT ID NCT07537010
First seen Apr 20, 2026 · Last updated May 22, 2026 · Updated 8 times
Summary
This early study tests a new drug (3D1015) that delivers radiation directly to prostate cancer cells in men with advanced, treatment-resistant prostate cancer. The main goals are to see if it is safe, how the body handles it, and what dose works best. Only 8 men will take part in this first phase.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangnan University Affiliated Hospital
RECRUITINGWuxi, Jiangsu, China
Contact
Conditions
Explore the condition pages connected to this study.